www.nature.com/nrurol N e w s & V i e w s laboratories are often derived by stratifying the readings of a healthy cohort into percentiles, but no agreement has been reached as to whether these cut-off points are valid in patients with mRCC. Finally, dichotomization is completely at odds with the concept of making optimal decisions, which relies on a function that takes all other predictors into consideration 4 . Finally, none of the blood variables currently included in the MSKCC and IMDC systems is sensitive for RCC or even for cancer, and the classification is dynamic. Indeed, the risk group into which the patient is classified can change quickly without intervention if blood values are close to the normal range or if performance status is assessed by another person. Additionally, cytoreductive nephrectomy has been shown to result in normalization of neutrophil and platelet counts in the majority of patients 5 . These factors can all result in a change in risk-group classification and management recommendations.
Little research has been conducted on the agreement in risk-group classification between the MSKCC and IMDC classification systems. Recently, Okita et al. 6 studied 176 patients with synchronous or asynchronous mRCC who received first-line sunitinib, sorafenib or axitinib. Although Cohen's κ-coefficient demonstrated good agreement between both classification systems in general, disagreement was seen in approximately
In patients with newly diagnosed metastatic renal cell carcinoma (mRCC), risk stratification is a crucial part of clinical assessment and essential for guiding management. Major clinical trials defining current treatment paradigms have relied on the Memorial Sloan Ketter ing Cancer Center (MSKCC) 1 or the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) 2 riskgroup classifications. Both were established using similar methodology and are fairly compar able with regard to variables and riskgroup assignment (Table 1 ). The MSKCC classification was developed using data from patients treated with cytokines, whereas the IMDC model was established using data from patients treated with targeted therapies. The IMDC classification uses markers of systemic inflammatory response such as neutrophil and platelet count, but the MSKCC classification uses lactate dehydrogenase (LDH) as a marker of cell death 1, 2 . Cur rent guidelines advocate the use of a model but do not recommend one in particular 3 . Even though treatment decisions are often made on the basis of the assigned risk group, both classifications have several shortcomings. First and foremost, concordance indices (such as the discrimination to predict survival) are low 2 , and both models are prognostic but not predictive. They do not consider metastatic site, tumour burden, histological type or molecular markers, which all might improve model discrimination. Furthermore, both classifications are mostly blood based and rely on dichotomized variables, both of which are problematic. Dichotomization of independent variables relies on statistical assumptions that are not reasonable, such as the association with the outcome being flat in each group. The cut-off points used in Perhaps the greatest potential of the Sangia test is for patients who are undergoing active surveillance for low-risk prostate cancer. These patients require frequent PSA level testing and concerns exist regarding patient compliance 4 . A simple point-of-care test stands to decrease the inconvenience of serial PSA testing and might possibly improve patient adherence to active surveillance protocols. However, notably, the initial data leading to approval of the device was obtained from patients without a known diagnosis of prostate cancer and, therefore, the utility outside of the initial detection setting has yet to be fully explored.
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...risk group disagreement between MSKCC and IMDC is common and generally associated with poor prognosis... one-quarter of patients. This involved a change from MSKCC intermediate-risk to IMDC poor-risk disease or vice versa in >80% of reclassified patients, and the majority of changes were related to the neutrophil count. Disagreement was associated with reduced progression-free survival (HR 1.9, P = 0.025) and overall survival (HR = 1.75, P = 0.028) 6 . Thus, disagreement is common, is prognostically relevant and has the potential to influence management.
The CARMENA trial 7 (NCT00930033) showed that sunitinib alone is not inferior to immediate cytoreductive nephrectomy followed by sunitinib in patients with synchronous metastatic clear cell RCC. The CARMENA trial relied on the MSKCC classification and stratified disease into intermediate risk and poor risk, which covers nearly 100% of patients with synchronous mRCC, as patients with this disease cannot be stratified into the favourable-risk group at the time of presentation. Only patients whose disease does not require systemic treatment for at least 1 year can be classified into the favourable-risk group, which can only be judged retrospectively. On the basis of prospective and retrospective evidence, the European Association of Urology guidelines 3 recommend not to perform cytoreductive nephrectomy in patients classified as having MSKCC poor-risk disease, not to perform immediate cytoreductive nephrectomy in patients classified as having MSKCC intermediate-risk disease with an asymptomatic primary tumour who require systemic treatment and to perform immediate cytoreductive nephrectomy in patients with good no effect on guideline-recommended first-line treatment. However, importantly, nearly 50% of patients with IMDC poor-risk disease could be reclassified to the MSKCC intermediate-risk group, whereas 50% would remain in the MSKCC poor-risk group according to the results of Okita and colleagues 6 . Evidence is insufficient to support use of sunitinib in patients with MSKCC poor-risk disease and, therefore, it might not be an alternative option for these patients if nivolumab plus ipilimumab is not feasible or safe.
In summary, risk group disagreement between MSKCC and IMDC is common and generally associated with poor prognosis, but the guideline-recommended first-line treatment remains unaltered in the vast majority of patients. Group disagreement could be routinely assessed as a prognostic factor in clinical practice and might improve discrimination of current models. 10 (NCT00083889) included patients of all prognostic groups, but risk group was assigned according to the MSKCC classification system. As a progression-free survival benefit of sunitinib was seen in all subgroups of patients 10 , and nivolumab plus ipilimumab was superior to sunitinib for IMDC intermediate-risk and poor-risk disease 9 , dis agreement between MSKCC and IMDC has Nature reviews | URology N e w s & V i e w s 
